pharmaceutical investing Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
pharmaceutical investing Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
pharmaceutical investing Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
pharmaceutical investing Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations
Red Metals Corp Invites Shareholders and Investment Community to Visit Them at Booth 2538 at PDAC 2026 in Toronto, March 1-4
